When rice is in its flowering and grain-filling stages, it is more sensitive to high nighttime temperatures than high daytime ...

EMERYVILLE, Calif. - Metagenomi, Inc. (NASDAQ: MGX), a biotechnology firm specializing in precision genetic medicines trading ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Colossal, values the Dallas-based startup at a staggering $10.2 billion. Besides making it the first startup founded in Texas ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

UK ministers are pressing ahead with legislation to adopt gene editing technology despite warnings from Brussels that it ...